Wolfteam Ltd.’s Post

A really useful article from my colleagues Jonathan GREENWOOD and Katharine Robinson Although it's framed in the biotech space, I think the useful tips in this post apply for any business owners contemplating an exit. So if that's you - it's definitely worth a read. #MergersAndAcquisitions #PrivateEquity #DealMaking #BusinessOwner #Entrepreneurs

Our #MarketUpdate report for the week ending February 9th is now available. Highlights include:    ➡️US equities continued to rally as the S&P 500 broke the 5,000 threshhold for the first time thanks to strong tech earnings and a better-than-expected January jobs report    ➡️Biotech IPOs continue to be active so far in 2024 with two additional companies completing their listings:    ➡️Kyverna Therapeutics raised $319.0M to fund their Phase 2 autoimmune cell therapy candidate    ➡️Metagenomi raised $93.8M to fund their preclinical gene-editing assets targeting a variety of indications    ➡️Last week saw two notable M&A deals announced:    ➡️Novo Holdings made headlines with their $16.5B acquisition of Catalent Pharma Solutions, a deal that will give Novo Nordisk additional manufacturing sites to increase the production of their highly popular obesity and diabetes drugs    ➡️Novartis announced that they had entered into an agreement to acquire MorphoSys AG for $2.9B, further strengthening their oncology pipeline    Read the full update here: https://bit.ly/42zh58M     #HealthcareMarket #oncology #gene #autoimmune #IPO #MarketTrends #BBLSA 

Our #MarketUpdate report for the week ending January 26th is now available. Highlights include:    ➡️ The Dow and S&P 500 both hit record highs this past week thanks in large part to a faster-than-expected GDP growth of 2.5% for the full 2023 calendar year     ➡️ IPOs are officially back – last week saw the first healthcare IPOs of 2024 price as three companies completed their listings, raising an aggregate $1.2B     ➡️ Two biotech companies – CG Oncology and ArriVent Biopharma raised $380.0M and $175.0M respectively for their late-stage cancer therapies on the Nasdaq     ➡️ BrightSpring Health Services, a healthcare service provider, raised $633.0M on the Nasdaq     ➡️ Sanofi made headlines with their $2.2B acquisition of Inhibrx, Inc., adding a potential best-in-class rare disease asset targeting Alpha-1 Antitrypsin Deficiency to their pipeline     ➡️ Venture investments saw an uptick in activity, with 13 private financings completed    Read the full update here: https://bit.ly/4bb0hsG       #HealthcareMarket #oncology #raredisease 

Our #MarketUpdate report for the week ending February 16th is now available. Highlights include:    🔉US equities ended the week with minor losses due to January’s CPI being higher than expected at 3.1% YoY and 0.3% MoM     🔉Despite the momentum that biotech IPOs have seen so far this year, last week saw no listings; however, 25 companies in the queue suggests that IPO activity will most likely remain elevated in the first half of the year     🔉Gilead Sciences made headlines by expanding their liver portfolio with their $4.3B acquisition of CymaBay Therapeutics, providing Gilead Sciences with CymaBay Therapeutics’s investigational lead candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) with FDA priority review and anticipated U.S. approval in the third quarter of 2024     🔉Freenome, developing blood tests for early cancer detection, raised a $254M venture round led by Roche and joined by a16z Life Sciences Growth Fund, Bain Capital Life Sciences Fund LP, RA Capital Management, and other flagship life sciences investors, making this deal the largest venture financing year-to-date    Read the full report here: https://bit.ly/42JY8k2     #Healthcare #MarketTrends #Biotech #IPO #Cancer #Theraputics #Lifesciences #BBLSA  

The first quarter of 2024 has been active on the M&A side for the Biotech sector with 13 deals (vs. a quarterly average of ~8 deals since 2018). Compared to January, IPO activity for the end of Q1 was quiet.

Our #MarketUpdate report for the week ending February 23rd is now available. Highlights include:    ➡️With markets heating up, prioritizing fundamentals in biotech investing ensures resilience against volatility and sustains long-term growth amidst dynamic market conditions    ➡️US equities continued to rally as the S&P 500 and Dow closed at all-time highs on Friday    ➡️Iovance Biotherapeutics, Inc. announced a $211.0M follow-on offering to fund the commercial launch of AMTAGVI, a novel polyclonal tumor-infiltrating lymphocyte therapy for the treatment cancer, in addition to current clinical trials    ➡️Ocular Therapeutix, Inc. made headlines by announcing a $325.0M PIPE to fund the clinical development of AXPAXLI, a hydrogel implant for the treatment of wet age-related macular degeneration (AMD), making this the largest PIPE/RDO announced in 2024 to-date    ➡️M&A and licensing transactions saw a decrease in activity relative to 2024 to-date as only two licensing deals were announced    Read the full update here: https://bit.ly/3SRPjQC     #healthcare #markettrends #cancertreatments #clinicaltrials #therapeutics #Biotech #BBLSA  

IPO & M&A Roundup for Biotech's - Q1 2024 💸 Exciting developments in the biotech world! Fierce Biotech's quarterly IPO and M&A roundup for Q1 2024 highlights the industry's continued growth and innovation. From groundbreaking mergers to IPO milestones, these trends underscore the dynamism of biotech. Stay updated on the latest advancements. Read more here: https://lnkd.in/eg-uifBT #Biotech #Innovation #IPO #MergersAndAcquisitions

Slow activity in Q2 – both M&A and IPOs – for the Biotech sector… confirming 1/ that the flurry of M&A dealmaking end of 2023 has cooled off in H1 2024 and 2/that the IPO market is still slow to recover (even if there have been tentative signs of improvement in recent months)

To learn something from the past, it is probably more insightful to look at the graveyard rather than the survivors, as pointed out in Nicholas Taleb's Black Swan.  Here's a nice snapshot of recent biotech acquisitions that didn't exactly go as planned. Do you see a pattern? https://lnkd.in/g8hWdcGU #biotechology

Nasdaq's IPO Pulse Index, a tool that assists investors in deciding when to go public, forecasts an upward trend for the first half of 2024. Several billion-dollar deals, such as immunotherapy company CG Oncology, are already in the works. Additionally, Reddit plans to go public in March, while Shein and Stripe are expected to make their debuts this year. If you're preparing for an IPO, you must have accurate and objective financial reports that clearly convey insights to your management team, investors, and other stakeholders. Bennett Thrasher is here to help. Our financial reporting service professionals work with business owners and executives to identify risks, plan transactions, and improve the quality of the information used to make vital decisions. #IPO #IPOPulseIndex #InitialPublicOffering #BennettThrasher https://lnkd.in/eCcbx5Df